Sugi Predict

Sugi Predict / Compounds / SCHEMBL477463

SCHEMBL477463

SCHEMBL477463

OC1CC(COCc2ccccc2)C1

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.50
▸ CTSL P07711 1/20 0.48
▸ CTSB P07858 1/20 0.48
▸ CTSK P43235 1/20 0.48
▸ AGTR2 P50052 1/20 0.46
▸ NAAA Q02083 1/20 0.44
▸ TAAR1 Q96RJ0 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ BUB1 O43683 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ PDE4D Q08499 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477464 1.00 TSHR (0.50) TSHRCTSLCTSBCTSKAGTR2
SCHEMBL598878 1.00 TSHR (0.50) TSHRCTSLCTSBCTSKAGTR2
Methoxymethane SCHEMBL967072 0.95 CTSL (0.48) TSHRCTSLCTSBCTSKAGTR2
Methoxymethane SCHEMBL967074 0.95 CTSL (0.48) TSHRCTSLCTSBCTSKAGTR2
Phosphoric Acid SCHEMBL599938 0.92 TSHR (0.46) TSHRCTSLCTSBCTSKAGTR2
SCHEMBL21783281 0.89 NAAA (0.43) TSHRCTSLCTSBCTSKAGTR2
SCHEMBL21783287 0.89 NAAA (0.43) TSHRCTSLCTSBCTSKAGTR2
SCHEMBL2933597 0.89 TSHR (0.50) TSHRCTSLCTSBCTSKAGTR2
SCHEMBL10279867 0.89 TSHR (0.50) TSHRCTSLCTSBCTSKAGTR2
SCHEMBL2933595 0.89 TSHR (0.50) TSHRCTSLCTSBCTSKAGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-12545684-B2 CDK2 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2026-02-10 — — US disclosed
EP-4634161-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2025-10-22 — — EP disclosed
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-10 — — US disclosed
US-20250059198-A1 BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2025-02-20 — — US disclosed
EP-4499634-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS Nikang Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
US-20240383902-A1 CDK2 INHIBITORS BLUEPRINT MEDICINES CORPORATION 2024-11-21 — — US disclosed
EP-4436966-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-10-02 — — EP disclosed
US-20050054658-A1 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists THOMPSON WAYNE (US) 2005-03-10 — — US disclosed
WO-2005019221-A1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2005-03-03 — — WO disclosed
EP-1212327-B8 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2004-02-25 — — EP disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed
EP-1212327-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2002-06-12 — — EP disclosed
WO-2001019829-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2001-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 TSHR 629/4885CTSL 3781/4885CTSB 4074/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 TSHR 334/4885CTSL 3323/4885CTSB 3635/4885
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF CCNA1, CCNE1, CCNA2 TSHR 358/4885CTSL 3267/4885CTSB 3540/4885
US-20250059198-A1 BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, RBX1, BRAP TSHR 3746/4885CTSL 4217/4885CTSB 2954/4885
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 TSHR 3442/4885CTSL 1663/4885CTSB 1259/4885
US-20240383902-A1 CDK2 INHIBITORS CDK2, CDK20, CDK2AP1 TSHR 3776/4885CTSL 2798/4885CTSB 3701/4885
US-12545684-B2 CDK2 inhibitors CDK2, CDK4, CDK1 TSHR 2101/4885CTSL 3389/4885CTSB 4199/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 TSHR 2200/4885CTSL 2371/4885CTSB 3543/4885
US-20050054658-A1 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists GRIN2B, GRIN1, GRIN2A TSHR 2076/4885CTSL 3982/4885CTSB 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.